Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma

Name: Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
License: Public Domain

Sun Yat-sen University

ClinicalTrials.gov · Datasets · License: Public Domain

hepatocellular carcinoma, neoadjuvant therapy, sintilimab, bevacizimab

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 217025
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.